← Leaderboards
David E Lanfear
Henry Ford Health System
$7,880,808
Attributed
$9,669,252
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $835.5K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,669,252 · 5
By mechanism
R01$6,642,504 · 2
P50$1,945,500 · 1
K23$631,800 · 1
R21$449,448 · 1
Top collaborators
- Hani N Sabbah4 shared
- Keoki Williams2 shared
Most similar at Henry Ford Health System
Same institution · by research overlap
- Oscar A. Carretero$13,917,720
- Jia L Zhuo$10,884,063
- Patrick J Pagano$9,459,985
- William H Beierwaltes$4,591,657
- Xiao-Ping Yang$6,327,825
Others in their field
Top investigators on “Heart Failure”
- Judith S Hochman · New York University School Of Medicine$120,321,606
- David T Mauger · Pennsylvania State Univ Hershey Med Ctr$51,947,333
- Lisa P Jacobson · Johns Hopkins University$45,397,923
- Walter N Kernan · Yale University$42,197,025
- Dalane W Kitzman · Wake Forest University$40,701,149
- David Couper · Univ Of North Carolina Chapel Hill$37,959,091
Research focus
Heart FailurePharmacotherapyPharmaceutical PreparationsVariantResponseCaringGeneticBrain Natriuretic PeptideLinkValidationAffectBaseClinical TrialsGenetic VariantGenomicsPharmacogeneticsProgramsResourcesEffectivenessGenesCohortFollow-UpCandidate Disease GeneAccounting
Grant awards (22)
ACHIEVE P2 - HF$335,635
P50 · FY2025 · MD · contact PI
Development of Polygenic Scores for Medication Response in Diverse Populations$202,672
R21 · FY2025 · HL · contact PI
ACHIEVE P2 - HF$310,406
P50 · FY2024 · MD · contact PI
Development of Polygenic Scores for Medication Response in Diverse Populations$246,776
R21 · FY2024 · HL · contact PI
ACHIEVE P2 - HF$425,287
P50 · FY2023 · MD · contact PI
ACHIEVE P2 - HF$518,643
P50 · FY2022 · MD · contact PI
ACHIEVE P2 - HF$355,529
P50 · FY2021 · MD · contact PI
Plasma Metabolomics and Myocardial Energetics in Heart Failure$763,273
R01 · FY2020 · HL · contact PI
Plasma Metabolomics and Myocardial Energetics in Heart Failure$763,414
R01 · FY2019 · HL · contact PI
Plasma Metabolomics and Myocardial Energetics in Heart Failure$795,434
R01 · FY2018 · HL · contact PI
Plasma Metabolomics and Myocardial Energetics in Heart Failure$805,320
R01 · FY2017 · HL · contact PI
Impact of Race and Genetic Factors on Beta-blocker Effectiveness in Heart Failure$671,146
R01 · FY2015 · HL · contact PI
Impact of Race and Genetic Factors on Beta-blocker Effectiveness in Heart Failure$641,643
R01 · FY2014 · HL · contact PI
Impact of Race and Genetic Factors on Beta-blocker Effectiveness in Heart Failure$622,291
R01 · FY2013 · HL · contact PI
Impact of Race and Genetic Factors on Beta-blocker Effectiveness in Heart Failure$213,175
R01 · FY2013 · HL · contact PI
Impact of Race and Genetic Factors on Beta-blocker Effectiveness in Heart Failure$672,286
R01 · FY2012 · HL · contact PI
Pharmacogenetics of the B-type Natriuretic Peptide Pathway$126,360
K23 · FY2012 · HL · contact PI
Impact of Race and Genetic Factors on Beta-blocker Effectiveness in Heart Failure$694,522
R01 · FY2011 · HL · contact PI
Pharmacogenetics of the B-type Natriuretic Peptide Pathway$126,360
K23 · FY2011 · HL · contact PI
Pharmacogenetics of the B-type Natriuretic Peptide Pathway$126,360
K23 · FY2010 · HL · contact PI
Pharmacogenetics of the B-type Natriuretic Peptide Pathway$126,360
K23 · FY2009 · HL · contact PI
Pharmacogenetics of the B-type Natriuretic Peptide Pathway$126,360
K23 · FY2008 · HL · contact PI